Cresemba

(Isavuconazonium)

Phase 3Small molecule

Astellas

Cresemba is one of 26 small molecule programs targeting Aspergillosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

AspergillosisActive, not recruiting

AspergillosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Aspergillosis

#DrugCompanyPhaseTrials

Vfend

PPrism Pharmaceuticals

Approved

13 2

Eraxis

VVicuron Pharmaceuticals

Approved

4 3

Mycamine

BBaxter Healthcare Corporation

Approved

4 4

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

3 5

Abelcet

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

3 6

Noxafil

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

3 7

Cancidas

FFresenius Kabi Oncology Ltd.

Approved

2 8

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—9

Versed

CConrado Roberto Hoffmann Filho

Ambisome

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Aspergillosis1 trial

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

Terminated·JJeffrey Jenks, MD, MPH·Phase 3·NCT04707703·8 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 6, 2015

CRESEMBA

NDA NDA207501

Nov 22, 2022

CRESEMBA

NDA NDA207500

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isavuconazonium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isavuconazonium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isavuconazonium. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA207500). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Cresemba. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Astellas

Patent Landscape[5]

Patent Cliff

Sep 14, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

6812238Oct 31, 2025

6812238*PEDApr 30, 2026

10603280Sep 14, 2027

10206879Sep 14, 2027

10603280*PEDMar 14, 2028

1 more patents

10206879*PEDMar 14, 2028

Cresemba

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Aspergillosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News